Minervax
Hellerup
About Minervax
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $215.5M
- Last round: Series Unknown (Oct 2023)
- Website: minervax.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Wellness
Canonical: https://fsome.com/organization/minervax-91695 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.